Adicet Bio is a biotechnology company that focuses on the development of allogeneic gamma delta T cell therapies for cancer. The company's proprietary technology platform enables the engineering of immune cells with improved properties for use in cancer immunotherapy. Adicet Bio's lead product candidate, ADI-001, is an allogeneic gamma delta T cell therapy that targets multiple tumor types. The company was founded in 2015 and is headquartered in Waltham, Massachusetts.